Testing effectiveness (Phase 2)UnknownNCT04984018
What this trial is testing
Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
Who this might be right for
Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University 73